白雲山(600332.SH):中一藥業新增生產車間和生產線
格隆匯4月11日丨白雲山(600332.SH)公佈,公司子公司廣州白雲山中一藥業有限公司(以下簡稱“中一藥業”)和廣州白雲山奇星藥業有限公司(以下簡稱“奇星藥業”)收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意中一藥業新增車間製造二部二區、新增散劑包裝生產線、丸劑包裝生產線、丸劑包衣生產線,中一藥業接受奇星藥業委託生產蛇膽陳皮散(國藥準字Z44020785)、華佗再造丸(國藥準字Z44020748)。
本次中一藥業新增生產車間和生產線、受託生產本公司子公司奇星藥業產品,有利於公司優化生產結構和資源配置,繼續保持穩定的生產能力,滿足市場需求,本次獲得《藥品生產許可證》,對本公司當期業績無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.